Email this article 
EFFECT OF IMMUNOTHERAPY ON THE CELLULAR IMMUNITY IN PATIENTS WITH CERVICAL CANCER
- Authors: Lazarev A.F.1, Kenbayeva D.K.2, Medeubayev R.K.3, Gorbatenko A.E.4, Tanatarov S.Z.4
-
Affiliations:
- Altai Regional Oncological Clinic, Barnaul, Russian Federation
- City Oncological Clinic of Astana, Republic of Kazakhstan
- Astana Medical University, Republic of Kazakhstan
- Semey State Medical University, Republic of Kazakhstan
- Issue: Vol 69, No 3-4 (2014)
- Pages: 5-8
- Section: ONCOLOGY: CURRENT ISSUES
- Published: 21.08.2015
- URL: https://vestnikramn.spr-journal.ru/jour/article/view/460
- DOI: https://doi.org/10.15690/vramn.v69.i3-4.987
- ID: 460
Cite item
Full Text
Abstract
For the last thirty years immunotherapy has become an integral part of treatment of some cancers. The most effective approach in this context would be the use of complex immunostimulatory factors including tumor antigen in different forms, interleukins that stimulate differentiation. Background: The aim of the study was to compare cellular immune response on specific and combined immunotherapy in patients with cervical cancer. Patients and methods: 76 cervical cancer patients undergoing combined radiotherapy were included into the study. Plus to basic radiation treatment two types of immunotherapy was performed: first — autolymphocytes reinfusion after in vitro incubation with tumor antigen (tumor tissue homogenate) and interleukin-2, second — combination of above mentioned immunotherapy, interleukin-2 and systemic enzyme. Results: This has resulted in increase of cellular immunity parameters in the main group with combined immunotherapy an excess of cells with killer activity to ensure an effective anti-tumor immune response and, accordingly, the clinical efficacy of specific methods and adoptive immunotherapy in patients with cervical cancer. Conclusion: Immunotherapy usage in the form of a preparation of interleukin-2 and a system enzymotherapy in a combination with a specific immunotherapy is possible. This way of treatment is recommended in cases of decreasing of cellular immunity indicators.
About the authors
A. F. Lazarev
Altai Regional Oncological Clinic, Barnaul, Russian Federation
Author for correspondence.
Email: aoc@ab.ru
доктор медицинских наук, профессор, директор Алтайского филиала ГУ «РОНЦ им. Н.Н. Блохина»
Адрес: 656000, Барнаул, ул. Никитина, д. 77, тел.: (385) 263-26-20 Россия
D. K. Kenbayeva
City Oncological Clinic of Astana, Republic of Kazakhstan
Email: dikenb@mail.ru
кандидат медицинских наук, заведующая отделением гинекологии Городского онкологического диспансера г. Астаны
Адрес: 010000, Астана, ул. Манаса, д. 17, тел.: (717) 254-20-30 Казахстан
R. K. Medeubayev
Astana Medical University, Republic of Kazakhstan
Email: rustemed@mail.ru
доктор медицинских наук заведующий курсом онкологии факультета усовершенствования врачей АО «Медицинский университет Астана»
Адрес: 010000, Астана, ул. Бейбитшилик, д. 53, тел.: (717) 253-94-55
A. E. Gorbatenko
Semey State Medical University, Republic of Kazakhstan
Email: aegorbat@mail.ru
ассистент кафедры специальных дисциплин Государственного медицинского университета г. Семей
Адрес: 071400, Семей, ул. Абая Кунанбаева, д. 103, тел.: (717) 256-42-09
S. Z. Tanatarov
Semey State Medical University, Republic of Kazakhstan
Email: sayat68@mail.ru
кандидат медицинских наук, ассистент кафедры специальных дисциплин Государственного медицинского университета г. Семей
Адрес: 071400, Семей, ул. Абая Кунанбаева, д. 103, тел.: (717) 256-42-09
References
- Harada Y., Yonemitsu Y. New technologies for immunotherapy against cancer: development of cell expansion technology and viruses as immune boosters. Yakugaku Zasshi. 2010; 130 (11): 1519–1526.
- Yaguchi T., Sumimoto H., Kudo-Saito C., Tsukamoto N., Ueda R., Iwata-Kajihara T., Nishio H., Kawamura N., Kawakami Y. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 2011; 93 (3): 294–300.
- Su J.H., Wu A., Scotney E. Ma B., Monie A., Hung C.F., Wu T.C. Immunotherapy for cervical cancer: Research status and clinical potential. BioDrugs. 2010; 24 (2): 109–129.
- Iga-Murahashi M., Hijikata Y., Suehiro Y., Inoue H., Tanaka Y., Shimoda S., Marumoto T., Okazai T., Yoshida K., Tsunoda T., Tani K. New strategies in anti-tumor immunotherapy. Rinsho Ketsueki. 2010; 51 (11): 1654–1660.
- Hamdy S., Haddadi A., Ghotbi Z., Hung R.W., Lavasanifar A. Part I: targeted particles for cancer immunotherapy. Curr. Drug Deliv. 2011; 8 (3): 261–273.
- O’Neill D.W. Dendritic cells and T cells in immunotherapy. J. Drugs Dermatol. 2010; 9 (11): 1383–1392.
- Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity’s roles in cancer suppression and promotion. Science. 2011; 331 (6024): 1565–1570.
- Onishi H., Suzuki H., Chikazawa N., Morisaki T., Katano M. New immunotherapy against cancer: a therapy to control regulatory T cell. Fukuoka Igaku Zasshi. 2010; 101 (10): 207–214.
- Ostrand-Rosenberg S., Sinha P., Danna E.A., Miller S., Davis C., Dissanayake S.K. Antagonists of tumor-specific immunity: tumor-induced immune suppression and host genes that co-opt the anti-tumor immune response. Breast Dis. 2004; 20: 127–135.
Supplementary files
